Ipamorelin vs GHRP-6: Selectivity, Side Effects, and GH Output

# Ipamorelin vs GHRP-6: Selectivity, Side Effects, and GH Output

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

Ipamorelin and GHRP-6 are both synthetic GH-releasing peptides (GHRPs) that stimulate GH secretion by activating the ghrelin receptor (GHS-R1a). They were developed by the same research group at Novo Nordisk in the 1990s and share the same primary mechanism of action, but differ substantially in their selectivity profiles — with important implications for their side effect profiles and research applications.

Receptor Pharmacology

Both Ipamorelin and GHRP-6 are agonists at GHS-R1a, the ghrelin receptor. GHS-R1a is expressed in the pituitary (where it mediates GH release), the hypothalamus (where it mediates appetite stimulation and somatostatin inhibition), and peripheral tissues including the heart, adipose tissue, and gastrointestinal tract.

The key pharmacological difference between the two compounds is their selectivity for GHS-R1a versus other receptors:

Ipamorelin: Highly selective for GHS-R1a with minimal activity at other receptors. Raun et al. (1998) demonstrated that Ipamorelin produced robust GH release in rats without significant effects on cortisol, prolactin, or ACTH — a selectivity profile not seen with any previously described GHRP.

GHRP-6: Less selective, with significant activity at receptors mediating cortisol and prolactin release. Bowers et al. (1990) documented that GHRP-6 produces dose-dependent increases in cortisol and prolactin in addition to GH — effects that are absent or minimal with Ipamorelin at equivalent GH-releasing doses.

Cortisol and ACTH Effects

The cortisol and ACTH effects of GHRPs are mediated through GHS-R1a receptors in the hypothalamus and pituitary that activate the HPA axis. GHRP-6 activates these receptors at doses that produce significant G H release, leading to measurable cortisol elevations of 30-60% above baseline in human studies.

Ipamorelin, by contrast, produces no significant cortisol or ACTH elevation at doses that produce maximal GH release. This selectivity is pharmacologically significant because chronic cortisol elevation has catabolic effects on muscle tissue, impairs immune function, and disrupts sleep architecture — effects that would counteract the anabolic goals of GH secretagogue research.

Appetite Stimulation

GHS-R1a receptors in the hypothalamus mediate ghrelin's orexigenic (appetite-stimulating) effects. GHRP-6 is a potent activator of hypothalamic GHS-R1a and produces significant appetite stimulation in both animal models and human subjects — an effect that can be substantial enough to limit its research utility in metabolic studies.

Ipamorelin produces minimal appetite stimulation at GH-releasing doses, consistent with its higher selectivity for pituitary versus hypothalamic GHS-R1a. This difference may reflect subtle differences in receptor binding kinetics or downstream signaling bias between the two compounds.

GH Output Comparison

Both compounds produce robust GH release, but the comparison of absolute GH output is complicated by dose-response differences and the different selectivity profiles.

At doses producing equivalent GH release, Ipamorelin has a cleaner side effect profile. At maximally effective doses, GHRP-6 may produce slightly higher peak GH levels due to its additional effects on somatostatin inhibition through hypothalamic pathways, but this advantage is offset by the cortisol and appetite effects.

Raun et al. (1998) demonstrated in rats that Ipamorelin produced GH release comparable to GHRP-6 at equivalent doses, with the key difference being the absence of cortisol and prolactin elevation with Ipamorelin.

Prolactin Effects

GHRP-6 produces dose-dependent prolactin elevation in addition to GH release. Elevated prolactin can cause gynecomastia in males, menstrual irregularities in females, and suppression of gonadotropin secretion — effects that are undesirable in most research contexts.

Ipamorelin produces no significant prolactin elevation, consistent with its high GHS-R1a selectivity and the absence of activity at receptors mediating prolactin release.

Research Application Implications

The selectivity differences between Ipamorelin and GHRP-6 have practical implications for research design:

- For studies examining GH/IGF-1 effects in isolation: Ipamorelin is preferred due to its clean selectivity profile that avoids confounding cortisol and prolactin effects - For studies examining appetite regulation: GHRP-6's appetite-stimulating effects may be a feature rather than a limitation - For combination with GHRH analogues: Ipamorelin is the standard choice due to its selectivity

References

1. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
2. Bowers, C.Y., et al. (1990). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545.
3. Arvat, E., et al. (1997). Preliminary evidence that Hexarelin, a synthetic GH-releasing peptide, suppresses endogenous somatostatin release in humans. Journal of Endocrinological Investigation, 20(5), 287–292.